Issues in assessing and reducing the risk for venous thromboembolism
- Association Between Perioperative Low-Molecular-Weight Heparin vs Unfractionated Heparin and Clinical Outcomes in Patients With Cancer Undergoing Surgery. Akl, Elie A.; Kahale, Lara A.; Schünemann, Holger J. // JAMA: Journal of the American Medical Association;4/7/2015, Vol. 313 Issue 13, p1364
The article provides information on a study comparing clinical outcomes between perioperative thromboprophylaxis using unfractionated heparin against low-molecular-weight heparin (LMWH) in patients with cancer. The results of trials found no differences between LMWH and unfractionated heparin in...
- ReplyRe: Anticoagulation in acute stroke patients with AF and prosthetic valves. Mudd, Paul D.; James, Martin A. // Age & Ageing;Sep2011, Vol. 40 Issue 5, p647
A response from Paul D. Mudd and Martin A. James to a letter to the editor about their article "Anticoagulation for atrial fibrillation: should warfarin be temporarily stopped or continued after acute cardioembolic stroke?" in the 2010 issue is presented.
- There's much R.Ph.s can do to improve anticoagulation. Hitchens, Kathy // Drug Topics;11/17/2003, Vol. 147 Issue 22, p36
Discusses the role of registered pharmacists in improving inpatient anticoagulation services in the U.S. Increase in the number of patients on anticoagulation and antithrombotic therapy; Management of heparin-induced thrombocytopenia; Ability of a pharmacist-run clinic to provide...
- Efficacy and Safety of Enoxaparin To Prevent Deep Venous Thrombosis after Hip Replacement Surgery. Spiro, Theodore E.; Johnson, Gerhard J.; Christie, Michael J.; Lyons, Roger M.; MacFarlane, Donald E.; Blasier, Ralph B.; Tremaine, M. David // Annals of Internal Medicine;7/15/94, Vol. 121 Issue 2, p81
Objective: To determine the most effective and safe dose of enoxaparin to prevent deep venous thrombosis in high-risk surgical patients. Design: A double-blind, randomized, multicenter clinical trial. Setting: Private, university, and government hospitals in the United States. Patients: 572...
- Venous thromboembolism and anticoagulants in pregnancy. // British Medical Journal;11/22/1975, Vol. 4 Issue 5994, p421
Describes the aspects of venous thromboembolism and anticoagulants in pregnancy. Risk of puerperal venous thromboembolism; Suppression of lactation by estrogens; Frequency of fatal pulmonary embolism.
- Elevated Plasma Factor VIII and D-Dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children. Goldenberg, Neil A.; Knapp-Clevenger, R.; Manco-Johnson, Marilyn J. // New England Journal of Medicine;9/9/2004, Vol. 351 Issue 11, p1081
Background: Elevated levels of plasma factor VIII and D-dimer predict recurrent venous thromboembolism in adults. We sought to determine whether an elevation of factor VIII, D-dimer, or both at diagnosis and persistence of the laboratory abnormality after three to six months of anticoagulant...
- Anticoagulant therapies: Review of available and upcoming agents. Tanzi, Maria G. // Pharmacy Today;Jan2011, Vol. 17 Issue 1, p58
Objectives: To identify clinical issues with warfarin therapy, differentiate between unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) and their respective advantages and disadvantages, explain the place in therapy for indirect and direct factor Xa inhibitors and direct...
- Strategies for diagnosing pulmonary embolism. // Patient Care;Mar2004, Vol. 38 Issue 3, p46
Discusses strategies for diagnosing pulmonary embolism (PE). Significance of rapid diagnosis and early treatment with anticoagulant therapy in the prevention of death associated with PE; Use of pulmonary angiography for diagnosing PE; Risk factors for venous thromboembolism.
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery. Eriksson, Bengt I.; Bauer, Kenneth A.; Lassen, Michael R.; Turpie, Alexander G.G. // New England Journal of Medicine;11/1/2001, Vol. 345 Issue 18, p1298
Background: Surgery for hip fracture carries a high risk of venous thromboembolism, despite the use of current thromboprophylactic treatments. Fondaparinux, a synthetic pentasaccharide, is a new antithrombotic agent that may reduce this risk. Methods: In a double-blind study, we randomly...